Company Profile
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Latest News
3M (MMM) Teams Up With Microsoft To Bring Optical Tech Into Azure AI Data Centers
Elon Musk's Starship Tries Again Today After Engine Abort, Weather Scrub: What Prediction Markets Say About Flight 13
Billionaire Investor Seth Klarman’s Top 5 Stocks: Would He Buy More Today?
Lightweight Inflatable Rooftop Tent Portal Nomis One Debuts on Kickstarter
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://beamtx.com |
| Audit Risk | 7 |
| Board Risk | 9 |
| Overall Risk | 7 |
| Market Cap | 2.58B |
| Forward P/E | -5.3 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | -0.49 |
| Forward EPS | -4.73 |
| Book Value | 11.72 |
| Price-to-Book | 2.14 |
| Enterprise-to-Revenue | 9.38 |
| Enterprise-to-EBITDA | -4.4 |
| Short Ratio | 8.56 |
| Earnings Date | 08/04/2026 |
| Earnings Call Date | |
| Earnings Average | -1.13 |
| Earnings Low | -1.24 |
| Earnings High | -0.95 |
| Revenue Average | 17.20M |
| Revenue Low | 10.00M |
| Revenue High | 33.30M |